NCT07602504Recruiting
China Metastatic Liver Cancer Clinical Registry Cohort Database
Source: ClinicalTrials.gov · Last updated 22 May 2026
Brief summary (registry, in English)
This study is led by the Department of Hepatobiliary Surgery of the First Affiliated Hospital of the University of Science and Technology of China (USTC), in close collaboration with multiple participating centers nationwide. The primary objective is to establish a standardized, large-scale clinical cohort database specifically for metastatic liver cancer. By collecting comprehensive data on patient demographics, primary tumor characteristics, systemic therapies, and local interventions, this registry aims to elucidate the clinical patterns and prognostic factors of secondary liver malignancies. This database will serve as a robust platform for conducting high-quality real-world studies and advancing evidence-based clinical research in the management of metastatic liver cancer.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 2000 (estimated)
- First submitted
- 16 May 2026
- Start date
- 1 Jun 2026
- Primary completion date
- 31 May 2031
- Lead sponsor
- Anhui Provincial Hospital
- NCT number
- NCT07602504
What you commit to
- Study type: Observational
- Planned participants: 2000
- From 1 Jun 2026 to the primary completion date, 31 May 2031
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have previously participated in other interventional clinical trials.
Other illness
- Patients with primary liver cancer (e.g., hepatocellular carcinoma).
- Patients with other malignant tumors that may interfere with the evaluation of liver metastasis.
- Patients with severe cognitive disorders or communication barriers that prevent informed consent.
Other
- Patients with incomplete or missing key clinical data.
Who the study is looking for
- Patients with histologically or radiologically confirmed metastatic liver cancer.
- Age ≥ 18 years.
- Patients who have voluntarily signed the informed consent form.
- Patients with complete baseline clinical data.
Age in the registry: 18 years to 80 years · Sex: All
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated Hospital of Bengbu Medical University Coordinator of this site? Confirm its status | Bengbu | China | Not yet recruiting |
| The First Affiliated Hospital of USTC(Anhui Provincial Hospital) Coordinator of this site? Confirm its status | Hefei | China | Recruiting |
| The Affiliated Hospital of Qingdao University Coordinator of this site? Confirm its status | Qingdao | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.